Disc Medicine To Participate In Upcoming Investor Conferences

2025-08-27 08:46:15

(MENAFN- GlobeNewsWire - Nasdaq) WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences:

Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 3^rd at 10:55 a.m. ET.

2025 Wells Fargo Healthcare Conference on Thursday, September 4^th at 4:30 p.m. ET.

H.C. Wainwright 27^th Annual Global Investment Conference on Tuesday, September 9^th at 12:00 p.m. ET.
Morgan Stanley 23^rd Annual Global Healthcare Conference on Wednesday, September 10^th at 1:05 p.m. ET.

Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit .

Media Contact

Peg Rusconi
Deerfield Group
...

Investor Relations Contact

Christina Tartaglia
Precision AQ
...

MENAFN27082025004107003653ID1109983332

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.